April 30, 2015
Daiichi Sankyo said on April 28 that it has slashed its FY2014 earnings estimates as it will record a write-off loss related to Zelboraf (vemurafenib), US subsidiary Plexxikon Inc.’s anticancer agent licensed to Swiss-based Roche. The Japanese drug maker will...read more